Indian Journal of Pharmaceutical Chemistry and Analytical Techniques (IJPCAT)
ISSN: 3049-3765 | Vol. 02, Issue-02, March-April, 2026, pp. 28-40
https://ijpcat.com/1

Role of Heterocyclic Compounds in Drug Discovery: A Comprehensive Review

Soundharya M[1], Saranya N[1*], Kanimozhli S N[1]

[1]Department of Biotechnology, Nehru Arts and Science College, Coimbatore, Tamil Nadu, India

***Corresponding Author E-mail: nascsaranya.n@nehrucolleges.com**

Abstract:

The heterocyclic compounds are a foundation of contemporary drug discovery due to their outstanding structural diversity, chemical versatility, and capacity to engage selectively with diverse biological targets. This is a comprehensive survey of the importance of heterocyclic scaffolds in pharmaceutical development with special emphasis on animal-based preclinical trials which offer important insights into the effectiveness of drugs, safety and drug mechanisms of action. It emphasizes their wide-ranging therapeutic possibilities in important fields like anticancer, antimicrobial, anti-inflammatory and central nervous system diseases. The review also discusses the key experimental methods, such as acute and chronic toxicity experiments, pharmacokinetic and pharmacodynamic tests, and disease specific animal models, which combine together to validate the preclinical development of these compounds. Further, it explains the importance of structural design, positive pharmacokinetic profiles, and multi-target mechanisms to improve drug functionality and therapeutic effects. New innovations (including nanotechnology-aided delivery of drugs, green synthesis, and the design of multi-functional heterocyclic agents) are also examined in a critical fashion. Although these developments have been made, several issues such as variability of species, ethical issues, scarcity of long-term toxicity data, and absence of standardized protocols continue to pose major obstacles to clinical translation. Thus, the review underscores how better experimental models, combination of computational and in vitro methods, and further innovation in the field of heterocyclic chemistry can be used to enable the production of safer, more effective and specific therapeutic agents in future.

Keywords: Heterocyclic Compounds; Drug Discovery; Animal-Based Studies; Pharmacokinetics; Mechanism of Action; Nanotechnology; Green Synthesis; Preclinical Evaluation.

Received: Jan. 13, 2026 **Revised: Feb. 13, 2026** **Accepted: March. 28, 2026** **Published: April 25, 2026**

DOI: https://doi.org/10.64062/IJPCAT.Vol2.Issue2.3

https://ijpcat.com/index.php/1/issue/archive

1. INTRODUCTION

Heterocyclic compounds are the basic types of organic molecules with ring structures, including heteroatoms including nitrogen, oxygen, or sulfur, which introduce characteristic chemical and biological characteristics. Their structural diversity, versatility and the capacity to react with a broad range of biological targets have rendered these compounds to become

indispensable in modern medicinal chemistry[1]. Heterocyclic scaffolds form the core of therapeutic innovation with a large percentage of clinically relevant drugs containing their structure. The development of synthetic methods, such as green chemistry and nanotechnology-based approaches, has also broadened the range of heterocyclic compounds and allowed designing molecules that are much more selective, have better pharmacokinetics, and lower toxicity.



Figure 1: Structures of Heterocyclic Compounds Containing N, O, and S Atoms[2]

The heterocyclic compounds are important in the field of drug discovery because they have shown a wide range of pharmacological properties, such as anticancer, antimicrobial, anti-inflammatory, and central nervous system activity. Animal-based preclinical studies are important in giving essential information regarding their effectiveness, mechanism of action, and safety profiles, which are important steps prior to clinical use[3]. These experiments can be used to carefully evaluate the behavior of the drug in complicated biological systems, such as absorption, distribution, metabolism, excretion and toxicity. Thus, the role and possibilities of heterocyclic compounds are critical to understanding the development of drugs and to coping with the increasing need to have more potent and specific therapeutic agents.

1.1 Background and Context

Heterocyclic compounds form an important category of organic molecules with structures in the form of a ring that includes at least one heteroatom, i.e., nitrogen, oxygen or sulfur. The compounds have wide application in the field of medicinal chemistry because they possess various chemical properties and can react well with biological systems[4]. Heterocyclic scaffolds are important in the design and development of modern therapeutic agents, as a significant proportion is based on the scaffold. Newer technologies in synthetic chemistry, nanotechnology, and green chemistry have added to the opportunities of heterocyclic compounds, making possible the creation of more efficient, selective, and safer drugs. Animal

experiments are important in this as they offer in vivo information on pharmacological activity, pharmacokinetics and toxicity, which contribute to the preclinical testing of these compounds.

1.2 Objectives of the Review

The primary objective of this review is to:

- To screen the pharmacological potential of heterocyclic compounds in animal-based models in the therapeutic fields of anticancer, antimicrobial, anti-inflammatory and CNS disorders.
- To examine the structural diversity and drug design approaches of heterocyclic compounds in improving efficacy, selectivity and safety.
- To investigate the pharmacokinetic properties and mechanisms of action of heterocyclic compounds in preclinical animal studies.
- To evaluate the methodologies, strengths, and weakness of animal-based evaluation of heterocyclic drug discovery.
- To identify new trends, research gaps, and future directions to enhance the development and translational potential of heterocyclic-based therapeutics.

1.3 Importance of the Topic

The heterocyclic compounds are highly relevant in pharmaceutical sciences because they are at the heart of the development of new therapeutic agents[5]. They are very useful to treat complex diseases including cancer, infections, inflammation and neurological conditions due to their ability to address many biological pathways. Moreover, the knowledge acquired during animal research is crucial in securing the safety, efficacy, and effective transfer to human practice. The insights into the progress and limitations of heterocyclic compounds will help to create more innovative, sustainable, and effective drug discovery approaches[6].

1. ANIMAL-BASED EVALUATION OF HETEROCYCLIC COMPOUNDS: METHODOLOGIES, APPLICATIONS, AND LIMITATIONS

The methodologies of animal-based include evaluating the safety, efficacy, and mechanisms of heterocyclic compounds through models such as rodents to examine the toxicity, pharmacokinetics and disease specific responses. Such works show great potential in therapeutic applications in anticancer, antimicrobial, anti-inflammatory and CNS applications, but the limitations of the results include species differences and ethical issues[7].

2.1 Overview of Animal-Based Methodologies

Animal models are significant in assessing the pharmacological activity, safety, and therapeutic potential of heterocyclic compounds prior to the clinical trials. These are models that offer a manipulated biological microenvironment that is highly similar to human physiological and pathological conditions and through the aid of which researchers can test drug behavior in vivo[8]. Rodents (mice and rats) are generally used as animal models because they are genetically similar, easy to handle, and cost-effective, and rabbits and zebrafish are also useful depending on their experimental applications: developmental studies and high-throughput screening.

Figure 2: Animal-Based Preclinical Evaluation of Drug Candidates[9]

Experimental Approaches:

- **Acute and chronic toxicity studies:** These experiments are done to determine the safety profile of the heterocyclic compounds with regard to time. Acute toxicity experiments determine the toxic effects of one or short-term dose and aid in determining lethal dose levels (LD_{50}) and acute toxicity. In contrast, chronic toxicity studies are a type of study that deals with long term exposure to the compound in order to determine long term effects, target organ toxicity, and possible cumulative toxicity[10].
- **Pharmacokinetic and pharmacodynamic assessments:** These assessments are concerned with the behavior of the drug in the body (pharmacokinetics) and the biological effects of the drug (pharmacodynamics). Pharmacokinetic studies look at parameters, including absorption, distribution, metabolism and excretion (ADME), whereas pharmacodynamic studies look at the connection between drug concentration and therapeutic response. Combined, these studies give information on the optimization of dosage, efficacy and duration of action.
- **Disease-specific models (tumor-bearing mice, inflammation-induced rats, infection models):** These models are meant to mimic certain diseases in humans so that they can specifically test the effectiveness of a drug. Indicatively, anticancer activity is examined with tumor-bearing mice, inflammation-induced rat models are used to determine the anti-inflammatory effects, and infection models are used to determine the antimicrobial effects. The disease-focused systems allow scientists to comprehend the therapeutic potential and mechanism of action of heterocyclic compounds in pathological conditions of interest.

These methodologies enable accurate tracking of drug efficacy, metabolism, and organ-differentiated effects, which can be deployed to offer necessary preclinical information on the development of heterocyclic-based therapeutics with safety and efficacy[11].

2.2 Key Research Studies and Findings

- **Anticancer Activity:** Experiments on heterocyclic molecules (e.g. pyridine and quinoline analogs) in tumor-bearing mice have shown that there is a substantial growth inhibition of tumors and also a decrease in tumor volume. The anticancer effects of these compounds are achieved by several different mechanisms, such as induction of apoptosis by caspase pathway activation, mitochondrial dysfunction, and angiogenesis

inhibition by inhibition of vascular endothelial growth factors. There are also reports that these compounds are capable of inhibiting cell proliferation and metastasis, and these compounds are potential candidates to develop anticancer drugs[12].

- **Antimicrobial Activity:** Imidazole and thiazole derivatives are heterocyclic compounds that exhibit high antibacterial and antifungal effects in diseased animals. The effects of these compounds include destabilization of microbial cell membranes, blocking of vital enzymes, and disrupting nucleic acid synthesis. Their use has been shown to be effective against a large variety of pathogenic microorganisms including those resistant to drugs, in vivo. Also, these compounds have been identified to increase host immune response that leads to the rapid elimination of infections and enhanced therapeutic results.
- **Anti-Inflammatory Activity:** Heterocyclic compounds have demonstrated a large decrease in inflammation in carrageenan induced rat paw edema models. They act by inhibiting cyclooxygenase (COX) enzymes, which in turn cause reduced synthesis of prostaglandin and inhibition of pro-inflammatory cytokines like TNF- alpha and IL-6. Moreover, such compounds have demonstrated antioxidant effects, decreased oxidative stress and tissue destruction, and thus, improved their total anti-inflammatory responses in preclinical trials[13].
- **Central Nervous System (CNS) Activity:** Behavioral tests on animals like maze tests, open field tests and forced swim tests have shown that heterocyclic compounds, especially indole derivatives, exhibit anxiogenic and antidepressant effects. Their main effects are ascribed to their capacity to regulate neurotransmitter systems, such as serotonin, dopamine, and gamma-aminobutyric acid (GABA). Also, there are compounds that have been shown to be neuroprotective because of their ability to decrease oxidative stress and enhance neuronal functioning, which indicates their potential to treat neurological and psychiatric diseases.



Figure 3: Pharmacological Activities of Heterocyclic Compounds[14]

2.3 Critical Evaluation

Strengths

There are a variety of benefits offered by animal research on heterocyclic compounds in preclinical research. They provide solid in vivo demonstrations of pharmacological activity, which enables the researcher to test the effects of drugs in an entire biological system. It is also through these studies that detailed evaluation of drug metabolism and systemic effects, absorption, distribution, metabolism and excretion (ADME) which are critical to the understanding of therapeutic efficacy are possible[15]. Moreover, animal models can be used to determine safe dose ranges and toxicity to aid researchers in establishing therapeutic index and any adverse effects that may occur on a particular organ before proceeding to clinical trials.

Limitations

Although animal studies have their advantages, there are also some limitations. Species differences are one of the biggest issues since physiological and genetic differences between animals and humans may restrict the direct applicability of the results to human conditions. Also, ethical questions about the use of animals exist and need to be strictly regulated and promote the creation of alternative ways of testing. The other significant limitation is the variability in the experimental conditions such as strain of animals, housing conditions, and experiment protocols, which can influence reproducibility and consistency of findings. Thus, animal research should be taken with a grain of salt and must be supplemented with additional research[16].

2. PHARMACOLOGICAL SIGNIFICANCE AND PRECLINICAL EVALUATION OF HETEROCYCLIC COMPOUNDS

Heterocyclic compounds are structurally diverse with good pharmacokinetics that allow better drug design with increased binding, bioavailability, stability, and localized distribution in animal models. They can work in various ways by enzyme inhibition and receptor interaction, and toxicity research shows that dose optimization must be carried out in order to provide safety and efficacy[17].

3.1 Structural Diversity and Drug Design

The heterocyclic compounds have tremendous structural diversity and flexibility and are thus very useful in contemporary drug design[18]. Their rings structures contain heteroatoms like nitrogen, oxygen or sulfur that provide diverse electronic and chemical properties. With such diversity, it is possible to make large-scale structural changes to maximize pharmacological action, enhance selectivity, and minimize toxicity. Hetero cycled nitrogen compounds are exceptionally important as they have the ability to bind strongly to the hydrogen bond as well as any electrostatic interactions with biological targets like enzymes and receptors. Such interactions increase binding specificity and affinity, so heterocyclic scaffolds are a fundamental element of numerous clinical therapeutics. Also, they have tunable physicochemical characteristics, allowing the construction of molecules with enhanced solubility and stability[19].

3.2 Pharmacokinetic Advantages

Animal research suggests that heterocyclic molecules tend to exhibit good pharmacokinetic behaviors as opposed to simpler organic molecules. These include:

- **Improved absorption and bioavailability:** Heteroatomic structure and highly optimized molecular structures increase solubility and absorption across biological membranes, especially through the gastrointestinal tract[20].
- **Enhanced metabolic stability:** The heterocyclic structures are able to withstand rapid degradation by enzymes leading to the long half-life and sustained therapeutic effects.
- **Favorable distribution across biological membranes:** A wide range of heterocyclic compounds are characterized by balanced lipophilicity and polarity, facilitating their efficient localization to tissues, including the capability to traverse some important barriers, such as the blood-brain barrier in some cases.

Such pharmacokinetic benefits lead to the enhancement of drug efficacy and a decrease in drug dosing in therapeutic practice[21].

3.3 Mechanism of Action

Heterocyclic compounds have many and frequently complementary pharmacological actions:

- **Enzyme inhibition:** Numerous heterocycles are competitive or non-competitive enzyme inhibitors, which inhibit major biochemical pathways that play a role in the development of diseases.
- **Receptor binding:** The compounds have the capacity to selectively bind cellular receptors, where they activate or inhibit signaling pathways to exert therapeutic effects.
- **DNA intercalation:** Some heterocyclic structures are able to slip between pairs of base pairs in DNA interfering with replication and transcription processes and this is used to advantage in anticancer therapy[22].
- **Signal transduction modulation:** Heterocyclic molecules have the ability to control intracellular signaling cascades, such as those involving kinases, to affect cell growth, apoptosis, and immunity.



Figure 4: Mechanisms of Action of Heterocyclic Compounds in Drug Discovery[23]

Their effectiveness is improved by the possibility to target various biological pathways, particularly in complex diseases, including cancer and neurological disorders.

3.4 Toxicological Evaluation

Investigations conducted on preclinical toxicity in animals have demonstrated that most of the heterocyclic compounds are rather safe upon administration at the right therapeutic doses. Safety profiles however differ based on chemical structure, dosage and length of exposure. Certain chemicals can cause adverse effects, including hepatotoxicity, neurotoxicity, or damages associated with oxidative stress, at higher doses or when used long-term[24].

Toxicological tests usually involve acute, sub-chronic and chronic toxicity tests, and biochemical, hematological, and histopathological tests. The studies are useful in recognizing target organ toxicity, defining safe dosage ranges, and determining the therapeutic index. Thus, optimal dose, structural adjustment and adequate preclinical trials are crucial in the safe and effective use of the heterocyclic compounds in drug development[25].

3. EMERGING TRENDS IN HETEROCYCLIC COMPOUNDS: INSIGHTS FROM ANIMAL-BASED STUDIES

Recent progress in heterocyclic chemistry has resulted in the emergence of new scaffolds, such as fused heterocycles and hybrid molecules, which are also being considered in animal models to improve performance in therapeutics. Such structurally complex compounds are better target specific and have improved biological activity because of their capability to bind in more than one location[26]. In vivo experiments in rodents have revealed that these compounds can substantially improve pharmacological effects of other disorders such as cancer, inflammation and microbial infections. Moreover, nanotechnology combined with heterocyclic compounds has created new opportunities in the field of targeted drug delivery, in which carriers made of nanoparticles enhance the solubility and stability of drugs and the localisation of accumulation of the substance, thereby minimising systemic toxicity.

The other notable trend is the use of green synthesis methods in the synthesis of heterocyclic compounds which are later tested by pharmacological experiments in animals[27]. Such environmental friendly processes reduce the generation of dangerous by-products and do not harm or completely destroy the biological effectiveness. Experiments involving animals have validated that heterocycles synthesized greenly still possess good therapeutic properties and low toxicity profiles. Moreover, the formation of multi-target heterocyclic drugs has also become a focus because they have the ability to target various biological pathways simultaneously, providing enhanced effectiveness in multifactorial diseases like cancer and neurological disorders. Animal disease models studies have demonstrated enhanced therapeutic effects in contrast to single target agents[28].

Advanced animal models such as transgenic mice and disease specific models have also been used and this has enhanced the evaluation of heterocyclic compounds in drug discovery. These models give a better understanding of the disease mechanisms and enable better evaluation of drug efficacy, pharmacokinetics and toxicity under more realistic biological conditions[29]. Consequently, they increase predictive potential of preclinical research and facilitate the gap between laboratory research and clinical practice. Overall, these new trends reflect a change of more efficient, sustainable, and focused strategies in the creation of heterocyclic-based therapeutics.

Table 1: Summary of Literature on Heterocyclic Compounds in Drug Discovery[30]

Author(s) & Year	Type of Heterocycle	Key Focus Area	Major Findings	Significance
Tahlan et al. (2019)[31]	Benzimidazole (1H-benzimidazole)	Pharmacological activities and SAR	Exhibited antimicrobial, anticancer, anti-inflammatory, and antiviral activities; structural modifications enhanced activity and selectivity	Identified benzimidazole as a versatile scaffold for drug development
De et al. (2021)[32]	Nitrogen & sulfur-containing heterocycles	Antiviral activity	Demonstrated broad-spectrum antiviral effects via inhibition of viral replication and enzyme interference	Highlighted importance in developing antiviral drugs for emerging infections
Nishanth Rao et al. (2021)[33]	Various heterocycles (green synthesis)	Green synthesis approaches	Eco-friendly methods (microwave, solvent-free, catalysts) maintained high yield and biological activity	Supported sustainable and environmentally friendly drug development
Bhat & Belagali (2020)[34]	Benzothiazole derivatives	Structure-Activity Relationship (SAR)	Showed anticancer, antimicrobial, and anti-inflammatory activities; substituent variation influenced activity	Reinforced SAR importance in designing effective therapeutic agents
Costa et al. (2021)[35]	Pyrazole analogs	Pharmacological evaluation & structural design	Exhibited anti-inflammatory, analgesic, and anticancer effects; structural optimization improved activity	Established pyrazole as a promising scaffold in medicinal chemistry

4. DISCUSSION

The structural diversity, multiple-target effects, and enhanced pharmacological delivery methods of heterocyclic compounds have proven to have high pharmacological potential in animal research and are essential in the context of contemporary drug discovery. Nevertheless, the issues such as species differences, lack of long-term toxicity data, and standardization emphasize the necessity of sophisticated models and combined research approaches to enhance clinical translation[36].

5.1 Interpretation and Analysis of Findings

The review notes that heterocyclic compounds hold a lot of pharmacological potential, evidenced by studies on animals. Their structural diversity and desirable pharmacokinetic qualities lead to improved drug efficacy, stability and target specificity. The animal models have revealed important information of their mechanisms of action, such as enzyme inhibition, receptor binding and biological pathway modulation, which have proven their efficacy in a

wide spectrum of therapeutic conditions, including cancer, infections, inflammation, and neurological conditions[37].

5.2 Implications and Significance

The results highlight the relevance of heterocyclic compounds in the development of modern drugs. They are also much more useful in treating complex diseases because of their capability to interact with several biological targets. Also, new technologies like nanotechnology-based delivery systems, green synthesis methods and multi-target drug design have led to a high level of enhancement in therapeutic effects and minimized toxicity in animals[38]. The developments show a transition to more effective, sustainable, and focused pharmaceutical approaches.

5.3 Research Gaps

Although promising, there are still a number of limitations. Differences in species between animal models and humans are a problem in the translation of preclinical results into clinical success. Reproducibility can be compromised by variability of experimental conditions, and non-standardized methodologies. In addition, a shortage of long-term toxicity data and in-depth studies of new heterocyclic structures indicate that further investigations are necessary[39].

5.4 Future Research Directions

Future studies should also aim at enhancing predictability and ethical nature of preclinical studies by combining the use of high animal models, computational and in vitro methods. There is also a need to develop standardized protocols to enhance reproducibility and reliability. New heterocyclic scaffolds to be investigated with improved safety profiles, as well as improvements in targeted drug delivery systems, will further enhance their use in drug discovery and aid in clinical translation[40].

5. CONCLUSION

Heterocyclic compounds are a backbone in the contemporary drug discovery as they are structurally diverse, have diverse chemical properties and can easily bind with various biological targets. Animal studies have played a critical role in determining their pharmacological effectiveness, safety, and mechanism of action, which have been fundamental preclinical data in therapeutic fields of anticancer, antimicrobial, anti-inflammatory and central nervous system disorders. The incorporation of sophisticated experimental techniques, such as pharmacodynamics and pharmacokinetics, toxicity, and disease-specific models has greatly enhanced the knowledge of drug Behavior in the complex biological systems. Moreover, the flexible structure and good pharmacokinetic properties of heterocyclic compounds foster better drug design, increased bioavailability and decreased toxicity. Their therapeutic potential has been further enhanced by the emergence of new technologies like nanotechnology-based drug delivery, green synthesis methods, and multi-target drug strategies. Nevertheless, issues such as species disparities, ethical issues, scarcity of long-term toxicity information and lack of standardization are obstacles to clinical translation. Thus, future studies are needed to combine sophisticated animal models with computational and in vitro methods, create standardized protocols, and investigate novel heterocyclic scaffolds to make the development of drugs safer, more efficient, and targeted.

REFERENCES

1. Kumar, N., & Goel, N. (2022). Heterocyclic compounds: importance in anticancer drug discovery. Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents), 22(19), 3196-3207.
2. Salah, A. R. M. (2025). Heterocyclic Compounds in Modern Drug Design: Synthetic Strategies and Biological Targets.
3. Al-Jumaili, M. H. A., Hamad, A. A., Hashem, H. E., Hussein, A. D., Muhaidi, M. J., Ahmed, M. A., ... & Bakr, E. A. (2023). Comprehensive review on the Bis–heterocyclic compounds and their anticancer efficacy. Journal of Molecular Structure, 1271, 133970.
4. Qadir, T., Amin, A., Sharma, P. K., Jeelani, I., & Abe, H. (2022). A review on medicinally important heterocyclic compounds. The Open Medicinal Chemistry Journal, 16(1).
5. Kabir, E., & Uzzaman, M. (2022). A review on biological and medicinal impact of heterocyclic compounds. Results in Chemistry, 4, 100606.
6. Kalaria, P. N., Karad, S. C., & Raval, D. K. (2018). A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery. European journal of medicinal chemistry, 158, 917-936.
7. Karthikeyan, S., Grishina, M., Kandasamy, S., Mangaiyarkarasi, R., Ramamoorthi, A., Chinnathambi, S., ... & John Kennedy, L. (2023). A review on medicinally important heterocyclic compounds and importance of biophysical approach of underlying the insight mechanism in biological environment. Journal of Biomolecular Structure and Dynamics, 41(23), 14599-14619.
8. Baranwal, J., Kushwaha, S., Singh, S., & Jyoti, A. (2023). A review on the synthesis and pharmacological activity of heterocyclic compounds. Current Physical Chemistry, 13(1), 2-19.
9. Obaid, R. J., Mughal, E. U., Naeem, N., Al-Rooqi, M. M., Sadiq, A., Jassas, R. S., ... & Ahmed, S. A. (2022). Pharmacological significance of nitrogen-containing five and six-membered heterocyclic scaffolds as potent cholinesterase inhibitors for drug discovery. Process Biochemistry, 120, 250-259.
10. Ahmed, S. A., Chopde, A. S., Yamnaji, A. B., & Pinjari, N. S. (2025). A Review on the Role of Heterocyclic Scaffolds in Drug Discovery. Journal of Pharma Insights and Research, 3(5), 394-402.
11. Mahurkar, N. D., Gawhale, N. D., Lokhande, M. N., Uke, S. J., & Kodape, M. M. (2023). Benzimidazole: A versatile scaffold for drug discovery and beyond–A comprehensive review of synthetic approaches and recent advancements in medicinal chemistry. Results in Chemistry, 6, 101139.
12. Rotella, D. P. (2021). Heterocycles in drug discovery: Properties and preparation. In Advances in heterocyclic chemistry (Vol. 134, pp. 149-183). Academic Press.
13. Ebenezer, O., Jordaan, M. A., Carena, G., Bono, T., Shapi, M., & Tuszynski, J. A. (2022). An overview of the biological evaluation of selected nitrogen-containing heterocycle medicinal chemistry compounds. International Journal of Molecular Sciences, 23(15), 8117.
14. Sharma, P. K., Amin, A., & Kumar, M. (2020). A review: Medicinally important nitrogen sulphur containing heterocycles. The open medicinal chemistry journal, 14(1).

15. Nadar, S., & Khan, T. (2022). Pyrimidine: An elite heterocyclic leitmotif in drug discovery-synthesis and biological activity. Chemical Biology & Drug Design, 100(6), 818-842.
16. Rusu, A., Moga, I. M., Uncu, L., & Hancu, G. (2023). The role of five-membered heterocycles in the molecular structure of antibacterial drugs used in therapy. Pharmaceutics, 15(11), 2554.
17. Singh, P. K., & Silakari, O. (2018). The current status of O-heterocycles: A synthetic and medicinal overview. ChemMedChem, 13(11), 1071-1087.
18. Sharma, V., Gupta, M., Kumar, P., & Sharma, A. (2021). A comprehensive review on fused heterocyclic as DNA intercalators: promising anticancer agents. Current Pharmaceutical Design, 27(1), 15-42.
19. Aatif, M., Raza, M. A., Javed, K., Nashre-ul-Islam, S. M., Farhan, M., & Alam, M. W. (2022). Potential nitrogen-based heterocyclic compounds for treating infectious diseases: a literature review. Antibiotics, 11(12), 1750.
20. Mangalagiu, I. I., & Mircea, D. (2025). Advances in the synthesis of heterocyclic compounds and their applications. Molecules, 30(18), 3723.
21. Laxmikeshav, K., Kumari, P., & Shankaraiah, N. (2022). Expedition of sulfur-containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update. Medicinal Research Reviews, 42(1), 513-575.
22. Lang, D. K., Kaur, R., Arora, R., Saini, B., & Arora, S. (2020). Nitrogen-containing heterocycles as anticancer agents: An overview. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 20(18), 2150-2168.
23. Heravi, M. M., & Zadsirjan, V. (2020). Prescribed drugs containing nitrogen heterocycles: an overview. RSC advances, 10(72), 44247-44311.
24. Hossain, M., & Nanda, A. K. (2018). A review on heterocyclic: Synthesis and their application in medicinal chemistry of imidazole moiety. Science, 6(5), 83-94.
25. Jampilek, J. (2019). Heterocycles in medicinal chemistry. Molecules, 24(21), 3839.
26. Khwaza, V., Mlala, S., Oyedeji, O. O., & Aderibigbe, B. A. (2021). Pentacyclic triterpenoids with nitrogen-containing heterocyclic moiety, privileged hybrids in anticancer drug discovery. Molecules, 26(9), 2401.
27. Amin, A., Qadir, T., Sharma, P. K., Jeelani, I., & Abe, H. (2022). A review on the medicinal and industrial applications of N-containing heterocycles. The Open Medicinal Chemistry Journal, 16(1).
28. Mirza, A. Z. (2019). Advancement in the development of heterocyclic nucleosides for the treatment of cancer-A review. Nucleosides, Nucleotides and Nucleic Acids, 38(11), 836-857.
29. Goni, L. K., Jafar Mazumder, M. A., Quraishi, M. A., & Mizanur Rahman, M. (2021). Bioinspired heterocyclic compounds as corrosion inhibitors: a comprehensive review. Chemistry–An Asian Journal, 16(11), 1324-1364.
30. Negi, M., Chawla, P. A., Faruk, A., & Chawla, V. (2020). Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic. Bioorganic Chemistry, 104, 104315.
31. Tahlan, S., Kumar, S., & Narasimhan, B. (2019). Pharmacological significance of heterocyclic 1 H-benzimidazole scaffolds: a review. BMC chemistry, 13(1), 101.

32. De, A., Sarkar, S., & Majee, A. (2021). Recent advances on heterocyclic compounds with antiviral properties. Chemistry of Heterocyclic Compounds, 57(4), 410-416.

33. Nishanth Rao, R., Jena, S., Mukherjee, M., Maiti, B., & Chanda, K. (2021). Green synthesis of biologically active heterocycles of medicinal importance: A review. Environmental Chemistry Letters, 19(4), 3315-3358.

34. Bhat, M., & Belagali, S. L. (2020). Structural activity relationship and importance of benzothiazole derivatives in medicinal chemistry: a comprehensive review. Mini-Reviews in Organic Chemistry, 17(3), 323-350.

35. Costa, R. F., Turones, L. C., Cavalcante, K. V. N., Rosa Júnior, I. A., Xavier, C. H., Rosseto, L. P., ... & Fajemiroye, J. O. (2021). Heterocyclic compounds: pharmacology of pyrazole analogs from rational structural considerations. Frontiers in Pharmacology, 12, 666725.

36. Alrooqi, M., Khan, S., Alhumaydhi, F. A., Asiri, S. A., Alshamrani, M., Mashraqi, M. M., ... & Aldahish, A. A. (2022). A therapeutic journey of pyridine-based heterocyclic compounds as potent anticancer agents: a review (from 2017 to 2021). Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents), 22(15), 2775-2787.

37. Jain, S., Chandra, V., Jain, P. K., Pathak, K., Pathak, D., & Vaidya, A. (2019). Comprehensive review on current developments of quinoline-based anticancer agents. Arabian Journal of Chemistry, 12(8), 4920-4946.

38. Alizadeh, S. R., & Ebrahimzadeh, M. A. (2021). Antiviral activities of pyridine fused and pyridine containing heterocycles, a review (from 2000 to 2020). Mini Reviews in Medicinal Chemistry, 21(17), 2584-2611.

39. Kaur, N., Kumar, V., Nayak, S. K., Wadhwa, P., Kaur, P., & Sahu, S. K. (2021). Alpha-amylase as molecular target for treatment of diabetes mellitus: A comprehensive review. Chemical biology & drug design, 98(4), 539-560.

40. El Mrayej, H., En-nabety, G., Ettahiri, W., Jghaoui, M., Sabbahi, R., Hammouti, B., ... & Taleb, M. (2025). Triazolopyrimidine derivatives: A comprehensive review of their synthesis, reactivity, biological properties, and molecular docking studies. Indonesian Journal of Science and Technology, 10(1), 41-74.